Vavricka John 4
4 · Atea Pharmaceuticals, Inc. · Filed Feb 2, 2022
Insider Transaction Report
Form 4
Vavricka John
Chief Commercial Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-01-31+135,000→ 135,000 totalExercise: $7.14Exp: 2032-01-30→ Common Stock (135,000 underlying)
Footnotes (1)
- [F1]The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2022.